Is NCT07799532 recruiting in Downey, CA?

Yes, NCT07799532 is currently recruiting participants at its Downey, CA location. This chronic spinal cord injury clinical trial is actively enrolling qualified participants.

How do I join the chronic spinal cord injury clinical trial in Downey?

To join this clinical trial in Downey, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Downey clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Chronic Spinal Cord Injury Clinical Trial in Downey, CA

About This Chronic Spinal Cord Injury Study in Downey

The goal of this clinical trial is to learn if NVG-291 can improve function in adults with chronic cervical motor-incomplete spinal cord injury. It will also learn about the safety of NVG-291. The main questions it aims to answer are: * Does NVG-291 improve hand function and daily activities? * What side effects do participants have when taking NVG-291? Researchers will compare NVG-291 to a placebo (a look-alike substance that does not contain NVG-291) to see if NVG-291 improves function in adults with chronic cervical motor-incomplete spinal cord injury. Participants will: * Take NVG-291 or a placebo by injection under the skin (subcutaneous) once daily for 12 weeks. * Attend clinic visits for checkups and safety tests. * Complete tests and questionnaires about hand function, walking, daily activities, and quality of life. * Take part in an interview about changes in their condition, within 14 days after the Week 12 visit.

Sponsor: NervGen Pharma

Who Can Participate

Inclusion Criteria

Provide written informed consent prior to any study-specific procedures.

Be 18 to 75 years of age, inclusive.

Have chronic cervical spinal cord injury resulting from acute traumatic injury occurring 1 to 10 years prior to randomization.

Have motor-incomplete cervical spinal cord injury as determined by International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) assessment at screening, meeting all of the following: American Spinal Injury Association (ASIA) Impairment Scale grade C or D; motor level at C7 or rostral on both the right and the left side; and a muscle grade of 1 or greater on ISNCSCI manual muscle testing in at least one lower-extremity key muscle function (L2 to S1) on either side.

Have documented traumatic spinal cord injury confirmed by historical and/or current magnetic resonance imaging (MRI) or computed tomography (CT).

Have a Walking Index for Spinal Cord Injury II (WISCI II) score of 0 to 14, inclusive.

Have a score of at least 2 on at least one GRASSP Prehension Ability grasp pattern (cylindrical grasp, lateral key pinch, or tip-to-tip pinch) in at least one upper extremity, no more than one grasp-pattern score of 4 in the qualifying upper extremity, and a combined (bilateral) GRASSP Quantitative Prehension score no greater than 34, of a possible 40, across the sum of the four Prehension Performance task scores for the right and left hand.

Be willing and able to comply with study visits, assessments, study procedures, and study drug administration requirements.

Female participants of childbearing potential and male participants must agree to use protocol-specified contraception during study participation.

Exclusion Criteria

Nontraumatic spinal cord injury, penetrating spinal cord injury, multiple noncontiguous spinal cord lesions, or anatomically complete spinal cord transection.

Ventilatory dependence, defined as invasive mechanical ventilation via tracheostomy, noninvasive ventilation for chronic respiratory failure, or diaphragmatic or phrenic nerve pacing. Continuous or automatic positive airway pressure (CPAP/APAP) used solely for obstructive sleep apnea is not exclusionary.

Any condition preventing adequate assessment of all four extremities.

Any neurological condition that could interfere with study assessments or interpretation of results, including multiple sclerosis, stroke, amyotrophic lateral sclerosis, dementia, or progressive syringomyelia.

History of uncontrolled seizures or any seizure within 6 months prior to screening.

Pregnant or breastfeeding.

History of substance abuse within 12 months prior to screening.

Evidence of spinal instability, persistent spinal stenosis, or spinal cord compression related to the original injury.

Prior treatment with central nervous system gene therapy. Prior treatment with a protein tyrosine phosphatase sigma (PTPσ) mimetic peptide. Stem cell or cell therapy within 12 months prior to screening.

Severe neuropathic pain inadequately controlled by medication.

Body mass index (BMI) \>40 kg/m².

Known hypersensitivity to cetirizine, mannitol, trehalose, or polysorbate 80.

Receipt of botulinum toxin injection within 6 months prior to screening or 4-aminopyridine within 7 days prior to first dose. Current intrathecal opioid use.

Current participation in another interventional clinical trial or prior exposure to NVG-291.

Receipt of prohibited medications or therapies intended to enhance neuroplasticity within protocol-defined restricted periods.

Presence of an implanted neurostimulation or brain-computer interface device, or current neurostimulation therapy, including spinal cord stimulation, neuromuscular stimulation, vagal nerve stimulation, or phrenic nerve stimulation.

Malignancy within 5 years prior to screening, except adequately treated non-melanoma skin cancer or cervical or breast carcinoma in situ.

Clinically significant hepatic disease, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3 × upper limit of normal, or severe renal impairment (estimated glomerular filtration rate \<30 mL/min/1.73 m²).

Any disease, injury, medical condition, social condition, or behavioral condition that could interfere with study participation, study assessments, interpretation of results, or compliance with study requirements, in the opinion of the investigator.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Downey?

Yes, this clinical trial (NCT07799532) has an active research site in Downey, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Chronic Spinal Cord Injury Treatment Options in Downey, CA

If you're searching for chronic spinal cord injury treatment options in Downey, CA, this clinical trial (NCT07799532) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Downey research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced chronic spinal cord injury specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all chronic spinal cord injury clinical trials near you to find additional studies recruiting in your area.

Chronic Spinal Cord Injury Clinical Trial in Downey, CA

Expert Care in Downey

IRB Approved

No-Cost Care

Apply for This Downey Location

Why Participate?

Simple Process